Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dx by dt: diagnostic intent over time

This article was originally published in Scrip

Executive Summary

If Roche acquires Illumina, as it seems fairly intent on doing despite repeated messages of rejection from the smaller company, then it will not be the first company to acquire a genome sequencing firm. It will however be the first pharmaceutical company to acquire two such companies and will in effect have cornered the market in high-throughput genome technology. And that is important for positioning Roche front and centre in oncology.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016132

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel